Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 20.07.2026 1 Adv Exp Med Biol 1 Adv Sci (Weinh) 1 Ann Diagn Pathol 1 Ann Med Surg (Lond) 1 Ann Transl Med 1 APMIS 1 Apoptosis 2 Arch Esp Urol 1 Bioinformatics 1 BJU Int 1 BMC Cancer 1 BMC Med Imaging 3 BMC Urol 1 Bull Cancer 1 Cancer Cell Int 1 Cancer Immunol Immunother 1 Cancer Lett 1 Cancer Manag Res 1 Cancer Med 1 Cancer Rep (Hoboken) 1 Cancer Treat Rev 5 Cancers (Basel) 1 Cell Commun Signal 1 Cell Rep 1 Cell Signal 1 Clin Cancer Res 3 Clin Genitourin Cancer 1 Curr Probl Cancer 2 Diagnostics (Basel) 1 Discov Oncol 1 Einstein (Sao Paulo) 1 Eur J Pharm Sci 1 Eur J Surg Oncol 1 Eur Urol 1 Eur Urol Focus 2 Eur Urol Open Sci 1 Front Immunol 5 Front Oncol 2 Indian J Urol 2 Int Braz J Urol 1 Int Immunopharmacol 1 Int J Clin Oncol 2 Int J Mol Sci 1 Int J Pharm 1 Intern Med 2 iScience 2 J Clin Med 1 J Pak Med Assoc 1 Medicine (Baltimore) 3 Minerva Urol Nephrol 1 Mol Cancer 1 Nat Biomed Eng 1 Nat Commun 1 Nat Nanotechnol 1 Open Med (Wars) 1 Pathol Int 1 Pol J Pathol 1 Q J Nucl Med Mol Imaging 1 Rheumatol Int 3 Sci Rep 1 Signal Transduct Target Ther 5 Transl Androl Urol 1 Trials 2 Urol Oncol 2 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Adv Exp Med Biol

1. SILVA A, Baltazar F, Afonso J
   Metabolic Reprogramming in the Bladder Cancer Microenvironment: Bridging Fundamental Research and Therapeutic Avenues for Cancer-Associated Fibroblasts.
   Adv Exp Med Biol. 2026;1501:145-164.
   PubMed         Abstract available
   
   

   
   Adv Sci (Weinh)

2. CHEN D, Zhang C, Xue S, Zeng Y, et al
   LRG1 Drives Pathological Angiogenesis by Disrupting Neutrophil Mitochondrial Homeostasis in Bladder Cancer.
   Adv Sci (Weinh). 2026 Jul 13:e76604. doi: 10.1002/advs.76604.
   PubMed         Abstract available
   
   

   
   Ann Diagn Pathol

3. WANG G, Cheng Y, Zhou X, Guo Y, et al
   SEPT9 methylation as a potential biomarker for uncovering latent malignancy in flat urothelial lesions.
   Ann Diagn Pathol. 2026;84:152653.
   PubMed         Abstract available
   
   

   
   Ann Med Surg (Lond)

4. ABID S, Qasim N, Qaisar A, Nadeem A, et al
   FDA approval of mitomycin hydrogel (Zusduri): a new non-surgical era for non-muscle-invasive bladder cancer (NMIBC).
   Ann Med Surg (Lond). 2026;88:3930-3934.
   PubMed         Abstract available
   
   

   
   Ann Transl Med

5. MARTIN EW, Aragon-Ching JB
   Circulating tumor DNA (ctDNA)-guided adjuvant therapy for muscle-invasive bladder cancer (MIBC): ready for primetime?
   Ann Transl Med. 2026;14:42.
   PubMed        
   
   

   
   APMIS

6. KARABULUT B, Dag O, Kosemehmetoglu K, Guner G, et al
   Can We Foresee Grade and Stage Progression in Mixed Low- and High-Grade Noninvasive Papillary Urothelial Carcinomas?
   APMIS. 2026;134:e70238.
   PubMed         Abstract available
   
   

   
   Apoptosis

7. YAO Y, Yang P, Niu S, Yang J, et al
   GLI2 confers ferroptosis resistance in bladder cancer by transcriptionally upregulating PRDX1.
   Apoptosis. 2026;31:191.
   PubMed         Abstract available
   
   

   
   Arch Esp Urol

8. PEREZ-BARTIVAS L, Leiva-Cepas F, Ponferrada D, Flores-Paco P, et al
   Immunohistochemistry-Based Molecular Subtyping in Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy.
   Arch Esp Urol. 2026;79:773-782.
   PubMed         Abstract available
   
   
9. YALCIN B, Tuncay E, Arslan S, Araci HE, et al
   Survival in Synchronous Versus Metachronous Bladder and Prostate Cancer.
   Arch Esp Urol. 2026;79:800-807.
   PubMed         Abstract available
   
   

   
   Bioinformatics

10. WANG G, Liu F, Chen Z, Davoli T, et al
    conMItion: an R package adjusting confounding factors for associations in multi-omics.
    Bioinformatics. 2026;42:btag472.
    PubMed         Abstract available
    
    

    
    BJU Int

11. DUAN Q
    Letter to the Editor regarding: reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
    BJU Int. 2026 Jul 17. doi: 10.1111/bju.70385.
    PubMed        
    
    

    
    BMC Cancer

12. MOHANTY P, Subhangini M
    Immunohistochemical evaluation of molecular subtypes in muscle invasive bladder cancer with demographic correlation.
    BMC Cancer. 2026 Jul 10. doi: 10.1186/s12885-026-16476.
    PubMed         Abstract available
    
    

    
    BMC Med Imaging

13. KONG J, Huang Y, Xing Y, Fang S, et al
    Unlocking the prognostic power of pathomics in bladder cancer: a machine learning odyssey across multiple centers.
    BMC Med Imaging. 2026;26:266.
    PubMed         Abstract available
    
    

    
    BMC Urol

14. KANG Y, Zhong G, Zhang Y, Chang Z, et al
    Exploring the response shift effects on patient-reported outcomes among postoperative bladder cancer patients: a qualitative study in China.
    BMC Urol. 2026 Jul 10. doi: 10.1186/s12894-026-02247.
    PubMed         Abstract available
    
    
15. ELDESOUKI S, Elmekresh A, Esmaeilpour H, Kumar S, et al
    When double-J stents become a risk: bilateral distal ureteric urothelial carcinoma following ureteric instrumentation: a case report.
    BMC Urol. 2026;26:166.
    PubMed         Abstract available
    
    
16. REN J, Lu J, Xiong Z, Zhang Y, et al
    Latent profile analysis of health-related quality of life in patients with bladder cancer and abdominal wall stomas: a multicenter cross-sectional study.
    BMC Urol. 2026 Jul 13. doi: 10.1186/s12894-026-02253.
    PubMed         Abstract available
    
    

    
    Bull Cancer

17. GAUCHER C, Vicier C, Guerin M
    [Update: Evolution in the management of metastatic urothelial carcinomas].
    Bull Cancer. 2026;113.
    PubMed         Abstract available
    
    

    
    Cancer Cell Int

18. XU Y, Xu J, Han C, Li Q, et al
    Bioinformatics analysis of PFKFB family in pan-cancer and preliminary exploration of PFKFB4 in bladder cancer.
    Cancer Cell Int. 2026 Jul 13. doi: 10.1186/s12935-026-04354.
    PubMed         Abstract available
    
    

    
    Cancer Immunol Immunother

19. ZSCHABITZ S, Bhatti I, Casuscelli J, Pachmayr LO, et al
    Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).
    Cancer Immunol Immunother. 2026;75:184.
    PubMed         Abstract available
    
    

    
    Cancer Lett

20. ZHUANG J, Yu H, Chen Y, Sun H, et al
    HDAC10 suppresses anti-tumour immunity by inhibiting ILF3-CXCL9 axis to block CD8(+) T cell infiltration and activation in bladder cancer.
    Cancer Lett. 2026;657:218729.
    PubMed         Abstract available
    
    

    
    Cancer Manag Res

21. SUI J, Chen Y, Jiang Y, He Q, et al
    Post-IMvigor011 Era: CtDNA-Guided Postoperative Adjuvant Treatment Stratification in Muscle-Invasive Bladder Cancer.
    Cancer Manag Res. 2026;18:609903.
    PubMed         Abstract available
    
    

    
    Cancer Med

22. LIN Y, Xiang N, Yang Y, Huang S, et al
    Shared Genetics of Kidney Function Traits and Bladder Cancer: A Genome-Wide Cross-Trait Analysis.
    Cancer Med. 2026;15:e72025.
    PubMed         Abstract available
    
    

    
    Cancer Rep (Hoboken)

23. GOTO T, Teramoto Y, Elahi Najafi MA, Yasui M, et al
    Role of Latrophilin-1 and Latrophilin-2 as Downstream Effectors of Androgen Receptor Signaling in Urothelial Tumorigenesis.
    Cancer Rep (Hoboken). 2026;9:e70624.
    PubMed         Abstract available
    
    

    
    Cancer Treat Rev

24. WAFA H, van Creij NCH, Guenther M, Noeparast M, et al
    Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates.
    Cancer Treat Rev. 2026;148:103173.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

25. KWINTA L, Konopka K, Okon K, Lobacz M, et al
    Pretreatment NPLH as a Potential Predictor of Pathologic Complete Response to Accelerated MVAC Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Comparison with NLR and PLR.
    Cancers (Basel). 2026;18:2046.
    PubMed         Abstract available
    
    
26. FIGOLS M, Gonzalez A, Fernandez-Saorin M, Bautista A, et al
    Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2026;18:2054.
    PubMed         Abstract available
    
    
27. YANG MH, Nagisetti Y, Mukundan A, Karmakar R, et al
    Early Classification of Bladder Cancer Using Spectrum-Aided Visual Enhancer (SAVE) and Deep Learning Models: A Non-Invasive Technology for Faster Detection.
    Cancers (Basel). 2026;18:2147.
    PubMed         Abstract available
    
    
28. MORA-GARIJO B, Rahman S, Xu H, Chatzkel J, et al
    Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications.
    Cancers (Basel). 2026;18:2174.
    PubMed         Abstract available
    
    
29. PAN Q, Shi Q, Zhao Y, Yu T, et al
    MKRN2-Mediated Degradation of IGF2BP3 Suppresses MYC and Enhances CDK4/6 Inhibitor Sensitivity in Bladder Cancer.
    Cancers (Basel). 2026;18:2164.
    PubMed         Abstract available
    
    

    
    Cell Commun Signal

30. KAMI REDDY KR, Putluri V, Piyarathna DWB, Park JH, et al
    Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression.
    Cell Commun Signal. 2026 Jul 14. doi: 10.1186/s12964-026-03058.
    PubMed         Abstract available
    
    

    
    Cell Rep

31. AI Z, Zhou H, Jiang L, Lang Y, et al
    YAP1 lactylation confers cisplatin resistance and prognostic value by suppressing ferroptosis via FOSL1 in bladder cancer.
    Cell Rep. 2026;45:117692.
    PubMed         Abstract available
    
    

    
    Cell Signal

32. WU K, Wang B, Chen Y, Zhou J, et al
    Corrigendum to "DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling" [Cellular Signaling, 2015 Sep 26; 27(12): 2515-2523].
    Cell Signal. 2026 Jul 14:112700. doi: 10.1016/j.cellsig.2026.112700.
    PubMed        
    
    

    
    Clin Cancer Res

33. LI Z, Izadmehr S, Hoffman-Censits J, Maughan B, et al
    Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial.
    Clin Cancer Res. 2026;32:2911-2920.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

34. YAJIMA S, Yoshida S, Imasato N, Chen W, et al
    Postoperative Management After Pathological Complete Response to Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer: An Exploratory Reconstructed Individual Patient Data Analysis.
    Clin Genitourin Cancer. 2026;24:102603.
    PubMed         Abstract available
    
    
35. CRUPI E, Cigliola A, Mercinelli C, Piacentini M, et al
    Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.
    Clin Genitourin Cancer. 2026;24:102583.
    PubMed         Abstract available
    
    
36. MAHONEY ME, Jiang DM, Diaz-Mejia N, Atenafu EG, et al
    Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC).
    Clin Genitourin Cancer. 2026;24:102599.
    PubMed         Abstract available
    
    

    
    Curr Probl Cancer

37. D'SOUZA AA, Groshen SG, Tsao-Wei D, Ruel N, et al
    Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.
    Curr Probl Cancer. 2026;63:101294.
    PubMed         Abstract available
    
    

    
    Diagnostics (Basel)

38. SIM KC, Kim MJ, Sung DJ, Park BJ, et al
    Diagnostic and Prognostic Non-Invasive Markers in Bladder Cancer.
    Diagnostics (Basel). 2026;16:1948.
    PubMed         Abstract available
    
    
39. CHEN Y, Cai L, Yang X, Tao Y, et al
    An Immunohistochemistry-Based Molecular Subtyping Approach for Capturing Clinical Outcome Heterogeneity in Bladder Cancer.
    Diagnostics (Basel). 2026;16:2055.
    PubMed         Abstract available
    
    

    
    Discov Oncol

40. YU D, Zhang Y, Tang J, Qing J, et al
    A machine learning-guided epithelial plasticity score refines prognostication and immune-context stratification in muscle-invasive bladder cancer.
    Discov Oncol. 2026 Jul 13. doi: 10.1007/s12672-026-05555.
    PubMed         Abstract available
    
    

    
    Einstein (Sao Paulo)

41. PEIXOTO GA, Salles MP, Amaro Junior E, Korkes F, et al
    Rigid cystoscopy versus flexible outpatient cystoscopy: the economic cost behind the epidemiological and social impact.
    Einstein (Sao Paulo). 2026;24:eGS1136.
    PubMed         Abstract available
    
    

    
    Eur J Pharm Sci

42. MEHMUD I, Peng L, Zhang Y, Liang R, et al
    Localized In-Situ Nanomedicine Synthesis Enables Copper-Mediated Cuproptosis for Effective Bladder Cancer Therapy.
    Eur J Pharm Sci. 2026 Jul 17:107613. doi: 10.1016/j.ejps.2026.107613.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

43. GUO Q, Li L, Beeraka NM, Zhang Y, et al
    Sex-specific divergence in global urological cancer trajectories to 2050: A dual-model projection analysis based on GLOBOCAN and GBD databases.
    Eur J Surg Oncol. 2026;52:111943.
    PubMed         Abstract available
    
    

    
    Eur Urol

44. GONTERO P, Mariappan P, Pradere B, Rai BP, et al
    EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update.
    Eur Urol. 2026 Jul 15:S0302-2838(26)02111-1. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    

    
    Eur Urol Focus

45. PATTOU M, Roupret M, Kamat A, Boorjian SA, et al
    Novel BCG Combination or Modified BCG Regimens in BCG-Naive High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Focus. 2026 Jul 15:S2405-4569(26)00115.
    PubMed         Abstract available
    
    

    
    Eur Urol Open Sci

46. NIELSEN NK, Milling RV, Hjort PB, Vasquez JL, et al
    Histopathological Advantages of En Bloc Resection in Non-muscle-invasive Bladder Cancer: A Multinational Randomised Controlled Clinical Trial.
    Eur Urol Open Sci. 2026;90:69-76.
    PubMed         Abstract available
    
    
47. NIELSEN NK, Hjort PB, Hansen EB, Graugaard-Jensen C, et al
    Substaging and Stratified Treatment of T1 Bladder Cancer - a Nationwide Register-Based Study.
    Eur Urol Open Sci. 2026;90:92-100.
    PubMed         Abstract available
    
    

    
    Front Immunol

48. WANG Z, Zhou Z, Yang S, Zhao Z, et al
    Glycolysis-mediated H3K18la modifications drive aggressive bladder cancer through metabolic and epigenetic reprogramming.
    Front Immunol. 2026;17:1777092.
    PubMed         Abstract available
    
    

    
    Front Oncol

49. NAJMROCKA M, Semeniuk A, Stec R
    Adverse effects of systemic therapy in a patient with urothelial bladder cancer and chronic kidney disease - a case report.
    Front Oncol. 2026;16:1733345.
    PubMed         Abstract available
    
    
50. MAJUMDER A, Dwyer Orr L
    Racial and ethnic differences in bladder cancer diagnosis, treatment, and specialty care access among Medicare fee-for-service beneficiaries: a cross-sectional study.
    Front Oncol. 2026;16:1797699.
    PubMed         Abstract available
    
    
51. ABUHASANEIN S
    Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics.
    Front Oncol. 2026;16:1845015.
    PubMed         Abstract available
    
    
52. CHEN H, Liu N, Chen X, Xian P, et al
    Safety and preliminary efficacy of Disitamab Vedotin combined with Toripalimab and concurrent radiotherapy in bladder-preserving treatment for HER2-positive invasive bladder cancer.
    Front Oncol. 2026;16:1880457.
    PubMed         Abstract available
    
    
53. ZHANG Q, Xu K, Chen Z, Li Z, et al
    Identification of key genes potentially associated with bladder cancer development by common plasticizers: an integrated transcriptomics and network toxicology study.
    Front Oncol. 2026;16:1784832.
    PubMed         Abstract available
    
    

    
    Indian J Urol

54. AGRAWAL S, Pal AK, Sharma S, Tanwar R, et al
    The immunotherapy paradox in high-risk non-muscle-invasive bladder cancer: A tale of three trials.
    Indian J Urol. 2026;42:254-255.
    PubMed        
    
    
55. BAO W, Liu Y, Yang J, Ma X, et al
    The diagnostic value of biparametric magnetic resonance imaging vesical imaging-reporting and data system combined with tumor contact length for assessing muscle invasion in bladder cancer lesions scored vesical imaging-reporting and data system 3: A
    Indian J Urol. 2026;42:225-231.
    PubMed         Abstract available
    
    

    
    Int Braz J Urol

56. FARIA EF, Rodrigues A, Pompeo A, Fazoli A, et al
    Robot-Assisted Radical Cystectomy: Recommendations from Latin American Experts Consensus on Surgical Strategy, Urinary Reconstruction, and Oncological and Func-tional Outcomes.
    Int Braz J Urol. 2026;52:e20260431.
    PubMed         Abstract available
    
    
57. ASTUA IF, Suartz CV, Chade DC, Soares DFG, et al
    Bladder Cancer Management in Brazil's Supplementary Health System: Real-World Practice Patterns.
    Int Braz J Urol. 2026;52:e20260218.
    PubMed         Abstract available
    
    

    
    Int Immunopharmacol

58. YANG H, Zhou C, Zhou Z, Zhang F, et al
    Corrigendum to "YBX1 takes actions on triggering M2-like polarization of macrophages and stabilizing CXCL8 mRNA to exhibit its metastatic potential in bladder cancer" [Int. Immunopharmacol. 184 (2026) 116911].
    Int Immunopharmacol. 2026 Jul 17:117122. doi: 10.1016/j.intimp.2026.117122.
    PubMed        
    
    

    
    Int J Clin Oncol

59. BAI Z, Wang S, Wang H, Liu Z, et al
    Burden of bladder cancer in China from 1990 to 2023: temporal trends, modifiable risk factors, and implications for prevention.
    Int J Clin Oncol. 2026 Jul 15. doi: 10.1007/s10147-026-03139.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

60. BISSETTE RG, Congress Z, Nomdedeu-Sancho G, Wajih N, et al
    Bioprinted Bladder Cancer Organoids Model System for Prediction of Chemotherapy Response and Drug Screening.
    Int J Mol Sci. 2026;27:6082.
    PubMed         Abstract available
    
    
61. JERSINOVIC S, Vukovic M, Hennenlotter J, Lutfrenk T, et al
    Nectin-4 Expression in Muscle-Invasive Bladder Cancer Is Associated with Growth-Related and Inflammatory Signaling Pathways.
    Int J Mol Sci. 2026;27:5706.
    PubMed         Abstract available
    
    

    
    Int J Pharm

62. WANG W, Dong F, Lei J, Li L, et al
    Soluplus(R)-based solid dispersion enhances oral bioavailability of A10: a cGAS-STING and ICD activator for bladder cancer therapy.
    Int J Pharm. 2026;701:127190.
    PubMed         Abstract available
    
    

    
    Intern Med

63. FUKUMORI Y, Nishimura K, Tohi Y, Osaki Y, et al
    Prostatic Abscess Secondary to Postoperative Wound Infection Caused by Mycobacterium mageritense.
    Intern Med. 2026;65:1985-1989.
    PubMed         Abstract available
    
    

    
    iScience

64. CHEN DN, Wang JM, Zhang FH, Ye HY, et al
    KIF26B promotes bladder cancer progression through activating the NF-kappaB signaling pathway.
    iScience. 2026;29:116577.
    PubMed         Abstract available
    
    
65. ZHANG X, Wang H, Zhou H, Xiao D, et al
    An AI-powered diagnostic system for grading and invasion of non-muscle-invasive bladder cancer via TURBT specimens: A multicenter study.
    iScience. 2026;29:116651.
    PubMed         Abstract available
    
    

    
    J Clin Med

66. OZTURK MI, Ekici M, Aydin C, Caglayan MS, et al
    Preoperative Platelet-to-Lymphocyte Ratio as a Predictor of Recurrence and Recurrence-Free Survival in Non-Muscle-Invasive Bladder Cancer Across Different Intravesical Therapies.
    J Clin Med. 2026;15:5199.
    PubMed         Abstract available
    
    
67. CARRIERE PP, Hassanzadeh CJ
    Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions.
    J Clin Med. 2026;15:5101.
    PubMed         Abstract available
    
    

    
    J Pak Med Assoc

68. UYSAL E, Yilmaz Y, Akin Y, Gorgel SN, et al
    Demographic and histopathological features of patients with primary bladder cancer without recurrence in two-year follow-up.
    J Pak Med Assoc. 2026;76:1026-1032.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

69. ZHANG Z, Zhao Y, Li Z
    Multifocal xanthogranulomatous inflammation of the urinary tract mimicking metastatic urothelial carcinoma: A case report.
    Medicine (Baltimore). 2026;105:e49724.
    PubMed         Abstract available
    
    

    
    Minerva Urol Nephrol

70. ZHU Q, Wang J, Wei Y, Liu W, et al
    Preliminary feasibility of SHURUI single-port robot-assisted radical cystectomy with exploratory comparison to a contemporaneous da Vinci Xi single-port cohort.
    Minerva Urol Nephrol. 2026;78:383-388.
    PubMed         Abstract available
    
    
71. LO RE M, Cadenar A, Pezzoli M, Mancon S, et al
    Assessing the concordance between ChatGPT-4 and EAU guidelines indications in bladder cancer management: a real-world study.
    Minerva Urol Nephrol. 2026;78:411-418.
    PubMed         Abstract available
    
    
72. MASTROIANNI R, Tuderti G, Anceschi U, Bove AM, et al
    Robotic intracorporeal modified Bordeaux versus Padua ileal bladder: head-to-head surgical technique, perioperative and functional outcomes.
    Minerva Urol Nephrol. 2026;78:430-437.
    PubMed         Abstract available
    
    

    
    Mol Cancer

73. ZHAO G, Bai Y, Chen X, Li J, et al
    Remodeling of the tumor microenvironment in muscle-invasive bladder cancer: insights from single-cell and spatial transcriptomics after neoadjuvant immunochemotherapy.
    Mol Cancer. 2026 Jul 17. doi: 10.1186/s12943-026-02738.
    PubMed         Abstract available
    
    

    
    Nat Biomed Eng

74. GRIFFO A
    Nanosensor-integrated catheters for chemical mapping of bladder cancer biomarkers.
    Nat Biomed Eng. 2026;10:1274.
    PubMed        
    
    

    
    Nat Commun

75. PRIBUS SJ, Osredek I, Otonicar J, Simovic-Lorenz M, et al
    Multiomic profiling links L1 retrotransposition to genomic instability and ecDNA in bladder cancer.
    Nat Commun. 2026;17:6384.
    PubMed         Abstract available
    
    

    
    Nat Nanotechnol

76. LIN L, Li H, Zhou Q, Ding Q, et al
    Machine-intelligent multimodal algebot for intracavitary chemotherapy.
    Nat Nanotechnol. 2026;21:996-1007.
    PubMed         Abstract available
    
    

    
    Open Med (Wars)

77. HE X, Zhu H, Huang Y, Deng X, et al
    Analysis of the relationship between serum LAMC2, TROAP and clinical stages and prognosis of non-muscle invasive bladder cancer.
    Open Med (Wars). 2026;21:20261481.
    PubMed         Abstract available
    
    

    
    Pathol Int

78. SUZUKI S, Cohen SM
    Effects of Nicotine on Urinary Bladder Carcinogenesis.
    Pathol Int. 2026;76:e70151.
    PubMed         Abstract available
    
    

    
    Pol J Pathol

79. ATTYA ME, Sayed HY
    The clinicopathological significance of METTL3/SERPINE2 immunoexpression in urothelial carcinoma of the urinary bladder.
    Pol J Pathol. 2026;77:53-61.
    PubMed         Abstract available
    
    

    
    Q J Nucl Med Mol Imaging

80. GUGLIELMO P, Perrone E, Ozcan PP, Mapelli P, et al
    Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.
    Q J Nucl Med Mol Imaging. 2026;70:83-88.
    PubMed         Abstract available
    
    

    
    Rheumatol Int

81. GUPTA N, Kumar M, Phulware RH
    Bladder carcinoma associated with anti-NXP2-positive inflammatory myopathy: a case-based review.
    Rheumatol Int. 2026;46:207.
    PubMed         Abstract available
    
    

    
    Sci Rep

82. WANG H, Ji YA, Luo W, Xie Q, et al
    Memory B cells in mature follicle-like tertiary lymphoid structures predict BCG response in non-muscle-invasive bladder cancer.
    Sci Rep. 2026 Jul 15. doi: 10.1038/s41598-026-60910.
    PubMed         Abstract available
    
    
83. GU J, Wang M, Zhou Z, Zhang M, et al
    Associations between the intratumoral microbiome and the host transcriptome in bladder cancer and their implications for prognostic prediction.
    Sci Rep. 2026 Jul 11. doi: 10.1038/s41598-026-61819.
    PubMed         Abstract available
    
    
84. MALIK M, Sigorski D, Jacyk P, Rozycki M, et al
    ddMVAC versus gemcitabine-cisplatin as neoadjuvant treatment for muscle-invasive urothelial bladder cancer: a multicenter real-world study.
    Sci Rep. 2026 Jul 14. doi: 10.1038/s41598-026-60676.
    PubMed         Abstract available
    
    

    
    Signal Transduct Target Ther

85. TSUJINO T, Yamazaki S, Sakamoto M, Yoshikawa Y, et al
    A ferroptosis-suppressive state drives resistance to bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer.
    Signal Transduct Target Ther. 2026;11:299.
    PubMed         Abstract available
    
    

    
    Transl Androl Urol

86. REN W, Yi J, Zeng M, Cheng H, et al
    The YTHDC1/HECW1/SMAD7 axis drives cisplatin resistance in bladder cancer.
    Transl Androl Urol. 2026;15:201.
    PubMed         Abstract available
    
    
87. HAN C, Miao L, Liu Y, Wang Y, et al
    Prognostic and immunological implications of a mitophagy-associated gene signature in bladder cancer.
    Transl Androl Urol. 2026;15:199.
    PubMed         Abstract available
    
    
88. ABOU CHAKRA M, Myers AA, Marchetti KA, Zakharia Y, et al
    Impact of age on the effectiveness of intravesical Bacillus Calmette?Guerin and gemcitabine/docetaxel in treatment-naive high-risk non?muscle?invasive bladder cancer.
    Transl Androl Urol. 2026;15:215.
    PubMed         Abstract available
    
    
89. GABRIEL PE, Ingles JC, Zhu A, Horowitz A, et al
    Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances.
    Transl Androl Urol. 2026;15:221.
    PubMed         Abstract available
    
    
90. TANG S, Wang X, Chen F, Zhang L, et al
    Identification of pyroptosis-related molecular subtypes and development of a subtype-derived six-gene prognostic signature for bladder cancer.
    Transl Androl Urol. 2026;15:200.
    PubMed         Abstract available
    
    

    
    Trials

91. SYNESI G, Lewis R, Kilburn L, Bliss J, et al
    Identifying underrepresented groups in oncology clinical trials using routinely collected data in an English academic trial setting.
    Trials. 2026;27:504.
    PubMed         Abstract available
    
    

    
    Urol Oncol

92. YAJIMA S, Yoshida S, Imasato N, Chen W, et al
    Enfortumab vedotin monotherapy, enfortumab vedotin plus pembrolizumab, and immune checkpoint inhibitor-based neoadjuvant therapy for muscle-invasive bladder cancer: A systematic review and meta-analysis.
    Urol Oncol. 2026 Jul 11:S1078-1439(26)00566.
    PubMed         Abstract available
    
    
93. MCGRATH J, Banerjee I, Ishiyama Y, Balaji KC, et al
    Network meta-analysis of immune checkpoint inhibitors in BCG-naive, high-risk non-muscle-invasive bladder cancer.
    Urol Oncol. 2026 Jul 14:S1078-1439(26)00565.
    PubMed         Abstract available
    
    

    
    Urology

94. MARTIN A, Shi C, Martinez GM, Britton C, et al
    Long-term Outcomes of Partial Cystectomy for Urothelial Carcinoma in the Era of Bladder Preservation.
    Urology. 2026;213:131-140.
    PubMed         Abstract available
    
    
95. KENNEDY-YOON D, Almohtasib J, Kaul S, Fleishman A, et al
    Association of Patient, Disease, and Socioeconomic Characteristics With Receipt of Intravesical Bacillus Calmette-Guerin Therapy From 2002-2017 and the Impact of BCG Supply Shortages.
    Urology. 2026;213:88-95.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum